News | June 22, 2022
AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Wedgewood Pharmacy operates compounding pharmacies that offers sterile and non-sterile compounded medications for animal patients in 50 states.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Subscribe To Our Newsletter & Stay Updated
